Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.
Calcitonin inhibits both osteoclast formation and bone resorption, and is a primary treatment for patients with hypercalcemia and increased bone turnover. However, the clinical utility of calcitonin is limited because patients become refractory to calcitonin after several days (the calcitonin "escap...
Gardado en:
| Publicado en: | J Clin Invest |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Clinical Investigation
1995
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC295397/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7814611/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI117634 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|